Spinal fusion with recombinant human growth and differentiation factor-5 combined with a mineralized collagen matrix.
The availability of recombinant osteoinductive growth factors and new osteoconductive matrices offers an alternative to the use of autogenous bone (autograft) for grafting indications. This study evaluates the bone-forming activity of a mineralized collagen matrix combined with recombinant human growth and differentiation factor-5 in a rabbit posterolateral spinal fusion model. The activity of three distinct matrix-growth factor formulations is assessed by radiographic, histologic, and mechanical strength methods. Results show that the radiographic density, histologic quality, and mechanical strength of fusion at 12 weeks post-treatment rank consistently within the treatment groups. Optimal formulations are shown to perform similar to autograft in both the rate and strength of fusion. Fusion rates as high as 80% are observed within specific matrix/growth factor formulations. The average biomechanical strength of treated motion segments in the most efficacious formulation is 82% higher than that obtained with autograft, although this difference is not statistically significant. The fusion mass formed in response to matrix/growth factor formulations is composed of normal trabecular bone with a thin outer cortical plate and modest hematopoietic bone marrow. These results demonstrate that the combination of a mineralized collagen matrix with recombinant human growth and differentiation factor-5 maximizes the inherent conductive and inductive properties of each component, respectively, to provide an effective alternative to autograft for bone grafting procedures.
Spiro
R C
RC
Department of Research, Orquest, Inc., Mountain View, California 94043, USA. rspiro@fibrogen.com
Thompson
A Y
AY
Poser
J W
JW
D000818:Animals; D019485:Bone Morphogenetic Proteins; D016025:Bone Transplantation; D002417:Cattle; D003094:Collagen / Q000008:administration & dosage*; D019245:Compressive Strength; D017102:Fracture Healing / Q000187:drug effects; D055428:Growth Differentiation Factor 5; D006133:Growth Substances / Q000008:administration & dosage*; D008159:Lumbar Vertebrae / Q000187:drug effects / Q000601:surgery; D008297:Male; D008422:Materials Testing; D010012:Osteogenesis / Q000187:drug effects*; D011817:Rabbits; D011994:Recombinant Proteins / Q000008:administration & dosage*; D013123:Spinal Fusion / Q000379:methods*
D019485:Bone Morphogenetic Proteins; C525893:GDF5 protein, human; D055428:Growth Differentiation Factor 5; D006133:Growth Substances; D011994:Recombinant Proteins; D003094:Collagen